Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon beta-1a · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1st Injection | EXPERIMENTAL | Manual injection with pre-filled syringe. |
| Single-use autoinjector | EXPERIMENTAL | Single-use autoinjector with Avonex pre-filled syringe |
| 1 | EXPERIMENTAL | serum-free avonex given IM |
| Name | Type | Description |
|---|---|---|
| Interferon beta-1a | DRUG | 30mcg, IM once-a-week |
| Single-use autoinjector | DEVICE | Single-use autoinjector with Avonex 30mcg pre-filled syringe |
Inclusion Criteria: * Must be using liquid AVONEX® to treat MS. In addition, the subject must be on liquid AVONEX® for 12 weeks prior to the Screening Visit. * Must have a BMI of 19 to 28 kg/m², inclusive, and a minimum body weight of 50 kg at Screening. * Must be able to physically demonstrate use...
Interferon Beta-1a is used for the treatment of Multiple Sclerosis (MS) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). It is being developed by Biogen Inc. (BIIB) and is currently in Phase 2 clinical trials for these neurological conditions.
Interferon Beta-1a is a small molecule that works by modulating the immune system to reduce inflammation in the central nervous system. It is specifically used to treat autoimmune conditions like Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyradiculoneuropathy by altering the body's immune response.
Interferon Beta-1a is developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. Biogen is conducting clinical trials to evaluate the drug's safety and efficacy in treating Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Interferon Beta-1a is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by the FDA. The drug is being studied for its potential to treat Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Interferon Beta-1a has completed two Phase 2 clinical trials. The first trial (NCT00099489) studied the drug in 67 patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. The second trial (NCT00912860) evaluated immunogenicity and safety in 155 patients with Multiple Sclerosis.
Yes, Interferon Beta-1a is the same as Avonex. Clinical trials for this drug include studies of Avonex in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multiple Sclerosis, as well as studies of serum-free Avonex and a single-use autoinjector for delivering pre-filled Avonex syringes.